26 June 2015: Articles
Wait!!! No Steroids for this Asthma…
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Abdelhamid Alsharif BEF , Amik Sodhi EF , Luis C. Murillo EF , Arthur S. Headley EF , Dipen Kadaria BEFGDOI: 10.12659/AJCR.893729
Am J Case Rep 2015; 16:398-400
Abstract
BACKGROUND: Strongyloides stercoralis (SS) is a parasite seen in certain parts of the USA and in people from other endemic areas. In these patients steroids might precipitate or exacerbate asthma. Apart from worsening of asthma, serious complications like hyperinfection syndrome and even death can occur in these patients if treated with steroids. Treatment is either ivermectin or albendazole based on severity of the disease. Clinicians have to be very careful when prescribing steroids in patients presenting with an exacerbation of asthma from areas endemic for Strongyloides stercoralis.
CASE REPORT: A young woman with history of asthma presented with complaints of nausea, vomiting, abdominal pain, wheezing, and dry cough. Physical examination revealed diffuse expiratory wheezing and mild diffuse abdominal pain without rebound or guarding. Laboratory results showed leukocytosis with eosinophilia. Stool studies showed Strongyloides stercoralis. Imaging revealed ground-glass opacities in the right upper and lower lobe along with an infiltrate in the lingular lobe on the left side. Bronchoscopy showed Strongyloides stercoralis. The patient was diagnosed with hyperinfection syndrome due to Strongyloides stercoralis most probably exacerbated by prednisone given for her asthma. Steroids were then discontinued and the patient was started on ivermectin. The patient improved with treatment. Repeat stool examination was negative for Strongyloides stercoralis.
CONCLUSIONS: Clinicians have to be very careful when prescribing steroids in patients presenting with an exacerbation of asthma who are from areas endemic for Strongyloides stercoralis and should test for it (preferably with serology test) before starting treatment.
Keywords: Antiparasitic Agents - therapeutic use, Asthma - therapy, Diagnosis, Differential, Glucocorticoids - contraindications, Ivermectin - therapeutic use, Strongyloides stercoralis - isolation & purification, Strongyloidiasis - therapy, Tomography, X-Ray Computed
Background
Corticosteroids are the cornerstone of management for asthma, and usually the response to treatment is excellent. However, steroids might precipitate or exacerbate asthma, which could be life-threatening, in patients infected with a parasite –
Case Report
A 31-year-old Hispanic woman with history of asthma, who emigrated from Mexico at age 14, presented with complaints of nausea, vomiting, abdominal pain, wheezing, and dry cough. She had recently been treated for asthma exacerbation with prednisone and was still taking it. She denied any occupational exposure, pets, smoking, and recent travel. Vital signs were: temperature 101°F, pulse 106/min, blood pressure 112/72 mmHg, and respiratory rate 22/min. Systemic examination revealed diffuse expiratory wheezing and mild diffuse abdominal pain without rebound or guarding. Laboratory results showed leukocytosis (11 900/mm3) with eosinophilia (32.2%), negative drug screen, and negative rapid HIV test. Stool studies showed
Discussion
Strongyloidiasis is an infection caused by
Pulmonary symptoms may include dry cough, shortness of breath, wheezing, and hemoptysis. Features suggestive of recurrent bacterial pneumonia are common in these patients. They may also develop asthma, which paradoxically worsens with corticosteroid use [1,2]. Apart from worsening of asthma, serious complications and death can occur in these patients treated with steroids [3,4]. Gram-negative sepsis is also commonly seen in patients with
Diagnosis is based on active investigation of the parasite by identification of the larvae in the stool, and a high index of suspicion should be maintained, especially in immunocompromised patients. Standard stool examination is very insensitive for detecting
Treatment of limited disease is with ivermectin or albendazole. Disseminated disease or hyperinfection syndrome may require discontinuation of immunosuppressive therapy and prolonged use of ivermectin alone or in combination with albendazole until the patient shows clinical improvement and has negative stool studies for at least 2 weeks (1 autoinfection cycle) [9,10]. Data on treatment methods are limited to case reports or case series. Use of albendazole alone may have difficulty in clearing the infection and its efficacy has been shown to be lower than that of ivermectin [11].
Conclusions
Due to increased risk of developing disseminated disease or hyperinfection syndrome, clinicians have to be very careful when prescribing steroids in patients presenting with an exacerbation of asthma from areas endemic for
References:
1.. Sen P, Gil C, Estrellas B: South Med J, 1995; 88(9); 923-27, pmid: 7660209
2.. Wehner JH, Kirsch CM, Kagawa FT: Chest, 1994; 106(3); 762-66, pmid: 8082356
3.. Newberry AM, Williams DN, Stauffer WM, Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis: Chest, 2005; 128(5); 3681-84, pmid: 16304332
4.. Rodriguez EA, Abraham T, Williams FK, Severe strongyloidiasis with negative serology after corticosteroids treatment: Am J Case Rep, 2015; 16; 95-98, pmid: 25690926
5.. Chu E, Whitlock WL, Dietrich RA: Chest, 1990; 97(6); 1475-77, pmid: 2347234
6.. Rosenblatt JE, Clinical importance of adequately performed stool ova and parasite examinations: Clin Infect Dis, 2006; 42; 979-80, pmid: 16511763
7.. Hirata T, Nakamura H, Kinjo N: Am J Trop Med Hyg, 2007; 77; 683-84, pmid: 17978071
8.. Caroll SM, Karthigasu KT, Grove DI, Serodiagnosis of human strongyloidosis by an enzyme- linked immunosorbent assay: Trans R Soc Trop Med Hyg, 1981; 75; 706-9, pmid: 7036430
9.. Segarra-Newnham M: Ann Pharmacother, 2007; 41(12); 1992-2001, pmid: 17940124
10.. Pornsuriyasak P, Niticharoenpong K, Sakaibunnan A, Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis: Southeast Asian J Trop Med Public Health, 2004; 35; 531-34, pmid: 15689061
11.. Muennig O, Pallin D, Challah C: Epidemiol Infect, 2004; 132; 1055-63, pmid: 15635962
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






